BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...Activity” ). Kenneth Moch has stepped down as president and CEO of neurodegenerative disorders company Cognition Therapeutics Inc....
BioCentury | Nov 5, 2019
Company News

Management tracks: Santhera, Acadia, Aeglea, Entrada, Kleo, Laboratory for Advanced Medicine, Imago, Glympse and Cognition

...of global product development and commercialization for the multiple sclerosis franchise at Biogen Inc. (NASDAQ:BIIB). Cognition Therapeutics Inc....
...hired James O’Brien as CFO. He was EVP of finance at Enzo Biochem Inc. (NYSE:ENZ). BioCentury Staff Cognition Therapeutics Inc. Glympse...
BioCentury | Jun 5, 2019
Company News

Management tracks: Settleman to lead Pfizer cancer R&D; plus Roivant, LabCorp and more

...SVP, head of technical operations. He was COO at Histogenics Corp. (NASDAQ:HSGX). Neurodegenerative disease company Cognition Therapeutics Inc....
BioCentury | Mar 2, 2018
Product R&D

Sigma for synapses

...By focusing on synapse protection instead of aggregate formation, Cognition Therapeutics Inc. has identified a new target for...
...an allosteric mechanism, preventing it from damaging the synapse (see “Bumped Out”). Figure: Bumped out Cognition Therapeutics Inc....
...via an allosteric mechanism that induces a conformational change in the oligomer receptor complex. Source: Cognition Therapeutics...
BioCentury | Nov 10, 2017
Clinical News

Cognition's CT1812 well tolerated in Phase Ib/IIa trial for AD

...bound beta amyloid oligomers and inhibits binding of beta amyloid oligomers to the receptor complex. Cognition Therapeutics Inc....
...to moderate Alzheimer’s disease Endpoint: Safety and pharmacokinetics Status: Phase Ib/IIa data Milestone: NA Jaime De Leon CT1812 Cognition Therapeutics Inc. Beta...
BioCentury | Jul 21, 2017
Product Development

Surrogate start

...will have to confirm it first before more companies start to use them,” he said. Cognition Therapeutics Inc....
...expects to start the Phase II trial of CT1812 this year. Companies and Institutions Mentioned Cognition Therapeutics Inc....
BioCentury | Oct 28, 2016
Company News

Cognition names Moch CEO

...Neuroscience therapeutics company Cognition Therapeutics Inc. (Pittsburgh, Pa.) hired Kenneth Moch as president and CEO, replacing Hank Safferstein...
BioCentury | Sep 14, 2015
Financial News

Cognition Therapeutics completes venture financing

Cognition Therapeutics Inc. , Pittsburgh, Pa. Business: Neurology, Chemistry Date completed: 2015-09-08 Type: Venture financing Raised: $12 million Investors: Golden Seeds LLC; Bios Memory; Cowtown Angels; Scale Investors; Dolby Family Ventures; Maine Angels; Ogden CAP; PLSG...
BioCentury | Jan 24, 2011
Financial News

Cognition Therapeutics completes venture financing

Cognition Therapeutics Inc. , Pittsburgh, Pa. Business: Neurology, Chemistry Date completed: 1/20/11 Type: Venture financing Raised: $2.5 million Investors: Golden Seeds; Tech Coast Angels; Breedlove Limited Family Partnership; TMC Investment Co.; Ogden CAP; M5Invest Partners; Pittsburgh...
BioCentury | Jul 20, 2009
Financial News

Cognition Therapeutics completes venture financing

Cognition Therapeutics Inc. , Pittsburgh, Pa. Business: Neurology, Chemistry Date completed: 7/16/09 Type: Venture financing Raised: $1.2 million Investors: Ogden CAP; M5Invest Partners; Pittsburgh Life Sciences Greenhouse; Innovation Works; individual investors WIR Staff...
Items per page:
1 - 10 of 10
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...Activity” ). Kenneth Moch has stepped down as president and CEO of neurodegenerative disorders company Cognition Therapeutics Inc....
BioCentury | Nov 5, 2019
Company News

Management tracks: Santhera, Acadia, Aeglea, Entrada, Kleo, Laboratory for Advanced Medicine, Imago, Glympse and Cognition

...of global product development and commercialization for the multiple sclerosis franchise at Biogen Inc. (NASDAQ:BIIB). Cognition Therapeutics Inc....
...hired James O’Brien as CFO. He was EVP of finance at Enzo Biochem Inc. (NYSE:ENZ). BioCentury Staff Cognition Therapeutics Inc. Glympse...
BioCentury | Jun 5, 2019
Company News

Management tracks: Settleman to lead Pfizer cancer R&D; plus Roivant, LabCorp and more

...SVP, head of technical operations. He was COO at Histogenics Corp. (NASDAQ:HSGX). Neurodegenerative disease company Cognition Therapeutics Inc....
BioCentury | Mar 2, 2018
Product R&D

Sigma for synapses

...By focusing on synapse protection instead of aggregate formation, Cognition Therapeutics Inc. has identified a new target for...
...an allosteric mechanism, preventing it from damaging the synapse (see “Bumped Out”). Figure: Bumped out Cognition Therapeutics Inc....
...via an allosteric mechanism that induces a conformational change in the oligomer receptor complex. Source: Cognition Therapeutics...
BioCentury | Nov 10, 2017
Clinical News

Cognition's CT1812 well tolerated in Phase Ib/IIa trial for AD

...bound beta amyloid oligomers and inhibits binding of beta amyloid oligomers to the receptor complex. Cognition Therapeutics Inc....
...to moderate Alzheimer’s disease Endpoint: Safety and pharmacokinetics Status: Phase Ib/IIa data Milestone: NA Jaime De Leon CT1812 Cognition Therapeutics Inc. Beta...
BioCentury | Jul 21, 2017
Product Development

Surrogate start

...will have to confirm it first before more companies start to use them,” he said. Cognition Therapeutics Inc....
...expects to start the Phase II trial of CT1812 this year. Companies and Institutions Mentioned Cognition Therapeutics Inc....
BioCentury | Oct 28, 2016
Company News

Cognition names Moch CEO

...Neuroscience therapeutics company Cognition Therapeutics Inc. (Pittsburgh, Pa.) hired Kenneth Moch as president and CEO, replacing Hank Safferstein...
BioCentury | Sep 14, 2015
Financial News

Cognition Therapeutics completes venture financing

Cognition Therapeutics Inc. , Pittsburgh, Pa. Business: Neurology, Chemistry Date completed: 2015-09-08 Type: Venture financing Raised: $12 million Investors: Golden Seeds LLC; Bios Memory; Cowtown Angels; Scale Investors; Dolby Family Ventures; Maine Angels; Ogden CAP; PLSG...
BioCentury | Jan 24, 2011
Financial News

Cognition Therapeutics completes venture financing

Cognition Therapeutics Inc. , Pittsburgh, Pa. Business: Neurology, Chemistry Date completed: 1/20/11 Type: Venture financing Raised: $2.5 million Investors: Golden Seeds; Tech Coast Angels; Breedlove Limited Family Partnership; TMC Investment Co.; Ogden CAP; M5Invest Partners; Pittsburgh...
BioCentury | Jul 20, 2009
Financial News

Cognition Therapeutics completes venture financing

Cognition Therapeutics Inc. , Pittsburgh, Pa. Business: Neurology, Chemistry Date completed: 7/16/09 Type: Venture financing Raised: $1.2 million Investors: Ogden CAP; M5Invest Partners; Pittsburgh Life Sciences Greenhouse; Innovation Works; individual investors WIR Staff...
Items per page:
1 - 10 of 10